These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Higuchi Y; Sumiyoshi T; Kawasaki Y; Matsui M; Arai H; Kurachi M Schizophr Res; 2008 Apr; 101(1-3):320-30. PubMed ID: 18321680 [TBL] [Abstract][Full Text] [Related]
46. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Hajós M Trends Pharmacol Sci; 2006 Jul; 27(7):391-8. PubMed ID: 16766049 [TBL] [Abstract][Full Text] [Related]
47. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia. Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472 [TBL] [Abstract][Full Text] [Related]
48. Optimized mismatch negativity paradigm reflects deficits in schizophrenia patients. A combined EEG and MEG study. Thönnessen H; Zvyagintsev M; Harke KC; Boers F; Dammers J; Norra Ch; Mathiak K Biol Psychol; 2008 Feb; 77(2):205-16. PubMed ID: 18060677 [TBL] [Abstract][Full Text] [Related]
49. Auditory sensory processing deficits in sensory gating and mismatch negativity-like responses in the social isolation rat model of schizophrenia. Witten L; Oranje B; Mørk A; Steiniger-Brach B; Glenthøj BY; Bastlund JF Behav Brain Res; 2014 Jun; 266():85-93. PubMed ID: 24613239 [TBL] [Abstract][Full Text] [Related]
50. Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. Guillem F; Chouinard S; Poulin J; Godbout R; Lalonde P; Melun P; Bentaleb LA; Stip E Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):934-45. PubMed ID: 16580765 [TBL] [Abstract][Full Text] [Related]
51. Decomposing the constituent oscillatory dynamics underlying mismatch negativity generation in schizophrenia: Distinct relationships to clinical and cognitive functioning. Hochberger WC; Joshi YB; Zhang W; Thomas ML; ; Braff DL; Swerdlow NR; Light GA Int J Psychophysiol; 2019 Nov; 145():23-29. PubMed ID: 30586570 [TBL] [Abstract][Full Text] [Related]
52. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients. Düring S; Glenthøj BY; Oranje B Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696 [TBL] [Abstract][Full Text] [Related]
53. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Light GA; Braff DL Arch Gen Psychiatry; 2005 Feb; 62(2):127-36. PubMed ID: 15699289 [TBL] [Abstract][Full Text] [Related]
54. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351 [TBL] [Abstract][Full Text] [Related]
55. Mismatch negativity and cognitive performance in the course of schizophrenia. Hirt V; Schubring D; Schalinski I; Rockstroh B Int J Psychophysiol; 2019 Nov; 145():30-39. PubMed ID: 30684515 [TBL] [Abstract][Full Text] [Related]
56. Effects of quetiapine on cognitive functions in schizophrenic patients: a preliminary single-trial ERP analysis. Zhang Y; Lehmann M; Shobeiry A; Höfer D; Johannes S; Emrich HM; Dietrich DE Pharmacopsychiatry; 2009 Jul; 42(4):129-34. PubMed ID: 19585390 [TBL] [Abstract][Full Text] [Related]
57. Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine. Hubl D; Kleinlogel H; Frölich L; Weinandi T; Maurer K; Holstein W; Czekalla J; Dierks T Psychopharmacology (Berl); 2001 Nov; 158(3):281-8. PubMed ID: 11713618 [TBL] [Abstract][Full Text] [Related]
58. Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Sehatpour P; Javitt DC; De Baun HM; Carlson M; Beloborodova A; Margolin DH; Carlton MBL; Brice NL; Kantrowitz JT Neuropsychopharmacology; 2022 Feb; 47(3):711-718. PubMed ID: 34667294 [TBL] [Abstract][Full Text] [Related]